孕期接种与婴儿百日咳疫苗IgG应答调节:不同疫苗配方的影响
该研究为一项大型随机对照试验的二次分析,比较了孕期接种Td或Tdap5疫苗的母亲所生婴儿在接种DTaP3或DTaP5后的百日咳抗原IgG水平。结果显示,婴儿接种DTaP5基础免疫后,Tdap免疫母亲所生婴儿的百日咳毒素IgG几何均值浓度显著低于Td免疫母亲所生婴儿(52.3 vs 83.5,p<0.001),而接种DTaP3的婴儿中两组无显著差异。母亲用Tdap5、婴儿用DTaP3的组合可能减弱Tdap相关的免疫调节。
要点
- 婴儿接种DTaP5基础免疫后,Tdap免疫母亲所生婴儿的百日咳毒素IgG GMC为52.3,显著低于Td免疫母亲所生婴儿的83.5(p<0.001)。
- 婴儿接种DTaP3基础免疫后,Tdap与Td免疫母亲所生婴儿的百日咳抗原IgG GMC相似。
- 加强免疫前后,婴儿接种DTaP3时两组IgG GMC均相似。
核心结论
- 母亲孕期接种Tdap5、婴儿接种DTaP5基础免疫时,婴儿百日咳抗原IgG GMC显著低于Td免疫母亲所生婴儿;而婴儿接种DTaP3时两组相似。
- 母亲用Tdap5、婴儿用DTaP3的组合可能减弱Tdap相关的免疫调节。
研究设计与样本
- 对一项大型随机对照试验进行二次分析,比较孕期接种Td或Tdap5的母亲所生婴儿按婴儿疫苗配方(DTaP3或DTaP5)分层后的百日咳抗原IgG水平。
主要发现
- 婴儿接种DTaP5基础免疫后,Tdap免疫母亲所生婴儿的百日咳毒素IgG GMC为52.3,Td免疫母亲所生婴儿为83.5,p<0.001。
- 婴儿接种DTaP3基础免疫后,Tdap与Td免疫母亲所生婴儿的百日咳抗原IgG GMC相似。
- 在DTaP加强免疫前后,婴儿接种DTaP3时Tdap与Td免疫母亲所生婴儿的IgG GMC均相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The IgG response following infant diphtheria-tetanus-acellular pertussis (DTaP) immunization is influenced by the formulation of the infant and/or the adult vaccine (Tdap) given during pregnancy. DTaP vaccines containing either 3 (DTaP3) or 5 (DTaP5) pertussis antigens are commonly used. By conducting a secondary analysis of a large randomized controlled trial, we compared IgG levels against pertussis vaccine antigens in children of Td- and Tdap5-vaccinated mothers, after stratifying by infant vaccine formulation. After immunization with a primary series of DTaP5, but not DTaP3, IgG GMCs against pertussis antigens were significantly lower in infants of Tdap-immunized mothers compared with infants of Td-vaccinated mothers (pertussis toxin: GMC = 52.3[Tdap5] vs 83.5[Td], p < 0.001). Before and after the DTaP booster dose, IgG GMCs were similar in infants of Tdap- and Td-immunized mothers specifically when infants received the DTaP3 vaccine. The combination of the TdaP5 vaccine for mothers and the DTaP3 vaccine for children could attenuate Tdap-associated immunomodulation.
引用
- Brousseau N, Angers-Goulet ME, Bastien R, et al. Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations. Vaccine. 2024. PMID: 38461048. doi:10.1016/j.vaccine.2024.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。